Personalis,

genome-scale diagnostics services

Flexible on-site

The team generally works at the office, but is provided with flexible work options (e.g. option to work remotely part-time).

👥51-200

📍Menlo Park, California

Personalis,

About Personalis,

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality.

What Personalis, is building

Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer-reviewed publication and commercial success.

Technologies used at Personalis,

Front-end (1)

Back-end (2)

C++

Company culture

Integrity

Respect

Funding rounds

Total Funding

$225.1M

Last funding round type

Post-IPO Equity

Company type

For Profit

Personalis, news and updates

Personalis, Inc. recognized as top spot on The Scientist’s Top 10 Innovations of 2022 on Dec 12th 22'.

Personalis, Inc. today announced its NeXT Personal ® cancer assay earned the top spot on The Scientist’s Top 10 Innovations of 2022 list.

Dec 12, 2022 | businesswire.com

Personalis, Inc. launched Next Personal assay on Nov 17th 21'.

Personalis, which launched its Next Personal assay last year, aims to include up to 1,000 targets by starting with whole-genome rather than exome-only tumor sequencing.

Nov 17, 2022 | genomeweb.com

Personalis, Inc. partners with Olink Holding AB

Personalis has joined with Duke University and Olink Proteomics to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer.

Oct 5, 2022 | genengnews.com

Personalis, Inc. partnered with BC Cancer on Aug 15th 22'.

Personalis will also work with BC Cancer to assess whether MRD testing in these patients has the potential to reduce healthcare spending compared to existing imaging tools.

Aug 14, 2022 | genomeweb.com

Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2021.

Jan 6, 2022 | BioSpace

Personalis, Inc. launched publication of study titled, A machine learning algorithm on Apr 12th 22'.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of its study titled, " A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity," in Nature Communications.

Jan 1, 2022 | businesswire.com

About Personalis,

What Personalis, is building

Technologies used at Personalis,